Laura C Coates1, Peter Nash2, Tore K Kvien3, Laure Gossec4, Philip J Mease5, Lawrence Rasouliyan6, Luminita Pricop7, Steffen M Jugl8, Kunal K Gandhi7, Corine Gaillez8, Josef S Smolen9. 1. Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Botnar Research centre, Windmill Road, Oxford OX3 7LD, UK. Electronic address: laura.coates@ndorms.ox.ac.uk. 2. School of Medicine, Griffith University, Brisbane, Australia. 3. Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway. 4. Sorbonne Université, GRC08, Paris France; Pitié Salpêtrière Hospital, APHP, Rheumatology Department, Paris, France. 5. Division of Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, WA, USA. 6. RTI Health Solutions, Barcelona, Spain. 7. Novartis Pharmaceuticals Corporation, East Hanover, USA. 8. Novartis Pharma AG, Basel, Switzerland. 9. Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria.
Abstract
OBJECTIVES: Remission (REM) or low disease activity (LDA) states were compared in a clinical trial setting of the FUTURE 2 study (NCT01752634) using Disease Activity Index for Psoriatic Arthritis (DAPSA) and Minimal Disease Activity (MDA) composite indices in secukinumab treated PsA patients. METHODS: The proportion of patients reaching DAPSA-REM (cut-off ≤4) or REM+LDA (≤14), and very low disease activity (VLDA; achieving 7/7 criteria) or MDA (≥5/7), were compared in the overall population, by prior use of anti-TNF therapy, and by time since diagnosis using as observed data. The proportion of patients who met individual core component and other variables of interest were also computed to assess residual disease activity in DAPSA-REM/REM+LDA states and VLDA/MDA responses. The relationship between DAPSA/MDA and patient reported outcomes (PROs), including health-related quality of life, physical function, and fatigue were assessed using mixed model for repeated measures. RESULTS: More patients could achieve DAPSA-REM or DAPSA-REM+LDA status than VLDA or MDA responses, respectively, at all the time points in the overall population, irrespective of anti‒TNF status and time since diagnosis. Higher proportion of patients reaching DAPSA-REM or VLDA achieved more thresholds of core components (joints, pain, patient and physician global assessments, and function) than DAPSA-REM+LDA or MDA over Week 104. There were differences with numerically higher proportion of patients achieving patient global assessment ≤10 mm and ≤20 mm, and physician global assessment ≤10 mm with MDA than with DAPSA-REM+LDA, and patient pain VAS ≤15 mm, PASI ≤1, HAQ ≤0.5 with VLDA or MDA than with DAPSA-REM or DAPSA-REM+LDA, respectively, through 104 weeks. Improvements in PROs were significantly better for patients in DAPSA-REM+LDA versus DAPSA-moderate+high disease activity status, and for MDA responders versus non-responders. CONCLUSION: These analysis add to the evidence that both DAPSA and MDA composite index measures can be used for evaluation of the status and treatment response utilizing a treat to target approach in PsA patients in a clinical trial setting and improve patient health related outcomes. FUNDING: The study and analysis was funded by Novartis Pharma AG, Basel, Switzerland.
RCT Entities:
OBJECTIVES: Remission (REM) or low disease activity (LDA) states were compared in a clinical trial setting of the FUTURE 2 study (NCT01752634) using Disease Activity Index for Psoriatic Arthritis (DAPSA) and Minimal Disease Activity (MDA) composite indices in secukinumab treated PsA patients. METHODS: The proportion of patients reaching DAPSA-REM (cut-off ≤4) or REM+LDA (≤14), and very low disease activity (VLDA; achieving 7/7 criteria) or MDA (≥5/7), were compared in the overall population, by prior use of anti-TNF therapy, and by time since diagnosis using as observed data. The proportion of patients who met individual core component and other variables of interest were also computed to assess residual disease activity in DAPSA-REM/REM+LDA states and VLDA/MDA responses. The relationship between DAPSA/MDA and patient reported outcomes (PROs), including health-related quality of life, physical function, and fatigue were assessed using mixed model for repeated measures. RESULTS: More patients could achieve DAPSA-REM or DAPSA-REM+LDA status than VLDA or MDA responses, respectively, at all the time points in the overall population, irrespective of anti‒TNF status and time since diagnosis. Higher proportion of patients reaching DAPSA-REM or VLDA achieved more thresholds of core components (joints, pain, patient and physician global assessments, and function) than DAPSA-REM+LDA or MDA over Week 104. There were differences with numerically higher proportion of patients achieving patient global assessment ≤10 mm and ≤20 mm, and physician global assessment ≤10 mm with MDA than with DAPSA-REM+LDA, and patientpain VAS ≤15 mm, PASI ≤1, HAQ ≤0.5 with VLDA or MDA than with DAPSA-REM or DAPSA-REM+LDA, respectively, through 104 weeks. Improvements in PROs were significantly better for patients in DAPSA-REM+LDA versus DAPSA-moderate+high disease activity status, and for MDA responders versus non-responders. CONCLUSION: These analysis add to the evidence that both DAPSA and MDA composite index measures can be used for evaluation of the status and treatment response utilizing a treat to target approach in PsA patients in a clinical trial setting and improve patient health related outcomes. FUNDING: The study and analysis was funded by Novartis Pharma AG, Basel, Switzerland.
Authors: Philip J Mease; Alexis Ogdie; Soumya D Chakravarty; Natalie J Shiff; Iris Lin; Robert R McLean; Wendi Malley; Rebecca L Spitzer; Arthur Kavanaugh; Joseph F Merola Journal: Drugs Real World Outcomes Date: 2022-10-15
Authors: Laura C Coates; Andrew G Bushmakin; Oliver FitzGerald; Dafna D Gladman; Lara Fallon; Joseph C Cappelleri; Ming-Ann Hsu; Philip S Helliwell Journal: Arthritis Res Ther Date: 2021-03-26 Impact factor: 5.156
Authors: Nienke J Kleinrensink; Frank T Perton; Juliëtte N Pouw; Nanette L A Vincken; Sarita A Y Hartgring; Mylène P Jansen; Saeed Arbabi; Wouter Foppen; Pim A de Jong; Janneke Tekstra; Emmerik F A Leijten; Julia Spierings; Floris P J G Lafeber; Paco M J Welsing; Marloes W Heijstek Journal: BMJ Open Date: 2022-10-10 Impact factor: 3.006
Authors: Laura C Coates; Josef S Smolen; Philip J Mease; M Elaine Husni; Joseph F Merola; Eric Lespessailles; Mitsumasa Kishimoto; Lisa Macpherson; Andrew J Bradley; Rebecca Bolce; Philip S Helliwell Journal: RMD Open Date: 2022-09